IVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

7 Analyst Rating

Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is 17.86 USD with a low forecast of 11.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.660

Low

11.00

Averages

17.86

High

26.00

Current: 4.660

Low

11.00

Averages

17.86

High

26.00

Guggenheim

Etzer Darout

Buy

downgrade

$13 -> $11

2025-11-18

Reason

Guggenheim

Etzer Darout

Price Target

$13 -> $11

2025-11-18

downgrade

Buy

Reason

Guggenheim analyst Etzer Darout lowered the firm's price target on Inventiva to $11 from $13 and keeps a Buy rating on the shares after updating the firm's model to incorporate the announcement of $172.5M in equity financing, which the company plans to use to fund continuation of the NATiV3 Phase 3 trial, initiate the outcome trial, and for commercialization activities.

Wolfe Research

Outperform

initiated

$13

2025-11-05

Reason

Wolfe Research

Price Target

$13

2025-11-05

initiated

Outperform

Reason

Wolfe Research initiated coverage of Inventiva with an Outperform rating and $13 price target.

Wolfe Research

Outperform

initiated

$13

2025-11-05

Reason

Wolfe Research

Price Target

$13

2025-11-05

initiated

Outperform

Reason

As previously reported, Wolfe Research initiated coverage of Inventiva with an Outperform rating and $13 price target, calling the Phase 3 NATiV3 topline readout "the single most important event for the company" expected in the second half of 2026 and telling investors that the firm is "constructive" heading into the data. The firm's analysis suggests lanifibranor could demonstrate superior fibrosis improvement efficacy over approved MASH therapies, the analyst noted.

H.C. Wainwright

Ananda Ghosh

initiated

$20

2025-09-03

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$20

2025-09-03

initiated

Reason

H.C. Wainwright analyst Ananda Ghosh assumed coverage of Inventiva with a Buy rating and $20 price target. The FDA's recent acceptance of the company's letter of intent for liver stiffness measurement as a surrogate endpoint adds positive regulatory momentum for Inventiva, the analyst tells investors in a research note.

Guggenheim

Buy

upgrade

$9 -> $13

2025-09-02

Reason

Guggenheim

Price Target

$9 -> $13

2025-09-02

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Inventiva to $13 from $9 and keeps a Buy rating on the shares. The firm has updated its estimates based on "increased enthusiasm" for the Metabolic-Associated Steatohepatitis market and at-launch target patient population, the analyst tells investors.

Piper Sandler

Overweight

initiated

$26

2025-08-27

Reason

Piper Sandler

Price Target

$26

2025-08-27

initiated

Overweight

Reason

Piper Sandler initiated coverage of Inventiva with an Overweight rating and $26 price target. The company is developing its lead asset, lanifibranor, in metabolic dysfunction-associated steatohepatitis with a Phase 3 readout in the second half of 2026, the analyst tells investors in a research note. The firm sees a buying opportunity at current share levels, saying Inventiva has an oral asset that is "de-risked" for probability of success.

Valuation Metrics

The current forward P/E ratio for Inventiva SA (IVA.O) is -2.51, compared to its 5-year average forward P/E of -5.02. For a more detailed relative valuation and DCF analysis to assess Inventiva SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.02

Current PE

-2.51

Overvalued PE

0.76

Undervalued PE

-10.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.10

Current EV/EBITDA

-6.45

Overvalued EV/EBITDA

0.73

Undervalued EV/EBITDA

-10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

47.12

Current PS

97.51

Overvalued PS

87.44

Undervalued PS

6.79

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 681.82% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IVA News & Events

Events Timeline

No data

News

2.0

11-28Benzinga

Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

2.0

11-28Benzinga

Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

9.0

11-28Globenewswire

Inventiva's Shareholders' Meeting Approves All Resolutions Except for the 5th One

People Also Watch

Frequently Asked Questions

What is Inventiva SA (IVA) stock price today?

The current price of IVA is 4.66 USD — it has increased 4.02 % in the last trading day.

What is Inventiva SA (IVA)'s business?

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

What is the price predicton of IVA Stock?

What is Inventiva SA (IVA)'s revenue for the last quarter?

Inventiva SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Inventiva SA (IVA)'s earnings per share (EPS) for the last quarter?

Inventiva SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Inventiva SA (IVA)'s fundamentals?

The market is revising No Change the revenue expectations for Inventiva S.A. (IVA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.73%.

How many employees does Inventiva SA (IVA). have?

Inventiva SA (IVA) has 123 emplpoyees as of December 17 2025.

What is Inventiva SA (IVA) market cap?

Today IVA has the market capitalization of 890.14M USD.